SHORT-TERM VERSUS LONG-TERM ADDITION OF CYPROTERONE-ACETATE TO BUSERELIN THERAPY IN COMPARISON WITH ORCHIECTOMY IN THE TREATMENT OF METASTATIC PROSTATE-CANCER

In an open, multicenter, three-armed, randomized study, we compared th e effects of short-term (2 weeks) and continuous addition of the antia ndrogen cyproterone acetate to the luteinizing hormone-releasing hormo ne agonist buserelin to those of orchidectomy in patients with advance d prostate cancer. No significant differences among the three treatmen t arms with respect to response rate, subjective response, time-to-pro gression, overall survival, and cancer deaths were observed. It was co ncluded that the short-term or continuous addition of cyproterone acet ate to buserelin administered intranasally did not improve treatment r esults compared to orchidectomy only.